# Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

> **NCT03829969** · PHASE3 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 514 (actual)

## Conditions studied

- Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

## Interventions

- **BIOLOGICAL:** Toripalimab

## Key facts

- **NCT ID:** NCT03829969
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2021-03-22
- **Final completion:** 2023-09-30
- **Target enrollment:** 514 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829969, "Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03829969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*